BioBridge Global is making significant contributions to the ongoing fight with cancer, the organization’s Chief Scientific Officer told members of The Blood & Tissue Center Foundation board of directors at their meeting on Monday.
From blood transfusions to helping produce advanced therapies, Scott Jones, PhD outlined the organization’s efforts.
“Blood and platelets are our first area of support – 33% of all transfusions today go to cancer patients. But we are involved in a lot more areas, including the development of new therapies.”
Scott Jones, PhD, Chief Scientific Officer
Among the departments at BioBridge Global working on moving new treatments forward is Research and Development.
“We have a very active R&D group here,” said Jones, who leads Research and Development at BioBridge Global.
The team is working on developing “carriers” for stem cells and other types of cells in bioreactors, which multiply the cells for further research and eventually for treatments. R&D is developing multiple tests for use in the development of cancer therapies, as well as testing platforms for cell production.
The organization is also working on process development – developing processes to scale up therapies produced by researchers in order to make it in usable quantities for treating patients.
An existing lab within QualTex Laboratories has expanded its focus to include testing of advanced therapies, Jones said.
“And the final piece of the puzzle is the manufacturing part,” he said. “We have our GenCure biomanufacturing lab at the VelocityTX technology incubator with a suite of clean rooms, with the capacity to manufacture cell therapies for a variety of cancers.”
